Showing results (971-980 of 1,192) with videos related to

Sort By:
Pageof 120
The Lancet. Oncology|March 13, 2016
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trialGuillermo Garcia-Manero, Pierre Fenaux, Aref Al-Kali, et al.
American Journal of Hematology|November 15, 2017
A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasmsRita Assi, Hagop M Kantarjian, Guillermo Garcia-Manero, et al.
Cancer|July 15, 2017
A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemiaElias Jabbour, Nicholas J Short, Farhad Ravandi, et al.
Cancer|September 8, 2016
Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemiaElias Jabbour, Nicholas J Short, Jeffrey L Jorgensen, et al.
Journal of Hematology & Oncology|June 27, 2026
Vibecotamab for measurable residual disease in acute myeloid leukemia and for myelodysplastic syndromes and chronic myelomonocytic leukemia after hypomethylating agent failure: a phase II studyNicholas J Short, Alex Bataller, Courtney D DiNardo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up resultsHagop M Kantarjian, Moshe Talpaz, Susan O'Brien, et al.
Blood Advances|November 2, 2022
Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AMLGhayas C Issa, Aram Bidikian, Sangeetha Venugopal, et al.
Blood|January 24, 2018
Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomideKoichi Takahashi, Boyu Hu, Feng Wang, et al.
JCO Oncology Practice|July 16, 2024
Outcomes of Patients With Newly Diagnosed AML and HyperleukocytosisFadi G Haddad, Koji Sasaki, Jayastu Senapati, et al.
Cancer|July 26, 2017
Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patientsPreetesh Jain, Hagop M Kantarjian, Ahmad Ghorab, et al.
Pageof 120